Nadroparin calcium

Nadroparin calcium
Clinical data
Trade names Fraxiparine, Fraxodi
AHFS/ International Drug Names
Routes of
SC (except for haemodialysis)
ATC code B01AB06 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 89% (SC dose)
Biological half-life 3.7 hours (SC dose)
Excretion clearance 21.4mL/min (+/- 7)
CAS Number 9005-49-6 N
DrugBank DB08813 N
ChemSpider none
KEGG D07510 N
ECHA InfoCard 100.029.698
Chemical and physical data
Molar mass 4300 g/mol
 NYesY (what is this?)  (verify)

Nadroparin (trade name, Fraxiparine or Fraxodi) is an anticoagulant belonging to a class of drugs called low molecular weight heparins (LMWHs). Nadroparin was developed by sanofi-synthelabo.

Nadroparin is used in general and orthopedic surgery to prevent thromboembolic disorders (deep vein thrombosis and pulmonary embolism), and as treatment for deep vein thrombosis. It is also used to prevent clotting during hemodialysis, and for treatment of unstable angina and non-Q wave myocardial infarction.[1]

For the treatment and prevention of DVT, the drug is administered as a subcutaneous injection (under the skin), usually around the stomach. Injections are given once or twice daily depending on the condition.[1]


This article is issued from Wikipedia - version of the 9/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.